M型磷脂酶A2受体抗原及免疫反应在膜性肾病中的研究进展  

Research progress of M-type phospholipase A2 receptor antigen and immune response in membranous nephropathy

作　　者：王鑫[1] 周芸[1,2] Wang Xin;Zhou Yun(Department of Nephrology,the Fifth Clinical Medical College of Shanxi Medical University,Taiyuan 030012,China;Department of Nephrology,Shanxi Integrated Traditional Chinese and Western Medicine Hospital,Taiyuan 030013,China)

机构地区：[1]山西医科大学第五临床医学院肾内科,太原030012 [2]山西省中西医结合医院肾内科,太原030013

出　　处：《中华肾脏病杂志》2024年第12期978-983,共6页Chinese Journal of Nephrology

基　　金：山西省自然科学基金(YDZJSX2021B014);山西省实验动物基因工程研究中心。

摘　　要：膜性肾病(membranous nephropathy,MN)是一种器官特异性的自身免疫性疾病,是成年人肾病综合征最主要的原因。70%~80%MN病例无确切的病因,称为原发性膜性肾病(primary membranous nephropathy,PMN),其中70%与M型磷脂酶A2受体(M⁃type phospholipase A2 receptor,PLA2R)相关。目前针对MN的治疗方案主要包括免疫抑制剂及B细胞耗竭等非特异免疫治疗方法,本文拟对PLA2R相关MN中的免疫反应的发生机制进行综述,旨在为MN的特异性免疫治疗提供理论依据及方向。Membranous nephropathy(MN)is an organ-specific autoimmune disease,which is the main cause of nephrotic syndrome in adults.In 70%-80%of patients,MN occurs without an identifiable underlying cause.Regarding primary MN(PMN),70%of which are associated with M-type phospholipase A2 receptor(PLA2R).At present,the treatment of MN primarily involves non-specific immunotherapy,such as immunosuppressants and B cell depletion.This review focused upon the mechanism of immune response in PLA2R-associated MN,aiming to provide theoretical basis and direction for specific immunosuppressive therapies in MN.

关 键 词：肾小球肾炎 膜性 B淋巴细胞 T淋巴细胞 受体 磷脂酶A2 HLA抗原 

分 类 号：R692[医药卫生—泌尿科学]